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The important issue addressed by the studies pre-
sented here is the mechanism of neutrophil-mediated
damage to endothelial and epithelial cells during in-
flammation. Binding of neutrophil-released granule
proteins to endothelial cells may be involved in vas-
cular damage in patients with inflammatory vascular
diseases. We have determined whether granule pro-
teins proteinase 3(PR3) and/or myeloperoxidase
(MPO) are internalized into endothelial cells, as ex-
amined by UV light, confocal, and electron micros-
copy. Coincident induction of apoptosis and/or the
generation of intracellular oxidants were monitored.
The results indicate that human endothelial cells (hu-
man umbilical vein endothelial cells, human umbili-
cal arterial endothelial cells, human lung microvas-
cular endothelial cells) internalize both PR3 and
MPO, which are detected on the cell surface, in the
cytoplasm, and possibly nuclear. Epithelial cells
(small airway epithelial cells) internalized MPO but
not PR3, implying that the mechanism of PR3 inter-
nalization may be cell-type specific and different from
that of MPO. Internalization of PR3, but not MPO,
correlated with activation of apoptosis. Internaliza-
tion of MPO correlated with an increase in intracellu-
lar oxidant radicals. The requirement for the proteo-
lytic activity of PR3 for the induction of apoptosis was
examined by generating PR3-truncated fragments that
did not contain the components of the catalytic triad. An
apoptotic function was localized to the C-terminal por-
tion of PR3. These studies reveal novel mechanisms by
which the neutrophil granule proteins PR3 and MPO
contribute to tissue injury at sites of inflammation.
(Am J Pathol 2001, 158:581–592)
Neutrophilic inflammatory infiltrate is a common pathologi-
cal feature in acute inflammatory disease.1–3 The primary
function of neutrophils is the phagocytosis and destruction
of microorganisms, which may result in acute inflammation
in the surrounding tissue. On sensitization by inflammatory
signals, neutrophils adhere to the endothelium adjacent to
the infected tissue. After attachment, the neutrophils mi-
grate to the infected site where they release oxygen radicals
and their internal constituents, including azurophilic granule
proteins.1–5 Of the components present in these granules,
special attention has been paid to PR3 and MPO, because
the discovery that patients with Wegener’s granulomatosis,
microscopic polyangiitis, and Churg-Strauss syndrome
have circulating anti-PR3 or anti-MPO autoantibodies.6–9 In
recent years, a number of potential pathogenic mecha-
nisms by which PR3 and MPO have detrimental effects on
tissues and cells have been evaluated in multiple experi-
mental models.10–14
Structurally, PR3 belongs to the serprocidin subgroup
of the chymotrypsin-like protease superfamily, comprised
of neutrophil elastase, cathepsin G, and azurocidin.15–17
With the exception of azurocidin, which is a pseudopro-
tease, these proteases degrade extracellular matrix mac-
romolecules, such as elastin, fibronectin, laminin, vitro-
nectin, and type IV collagen.4,5,18,19 Sequence analysis
of PR3 showed it to be identical to myeloblastin, a gene
cloned as a differentiation marker from promyelocytic
leukemia HL60 cells.20 PR3 has been shown to be in-
volved in retinoic acid-induced differentiation of HL60
cells.20 Apparently, retinoic acid indirectly activates PR3,
which then hydrolyzes hsp27/28, a component of mito-
genic signal transduction pathways.21,22 Other known
substrates of PR3 include transcription factors (nuclear
factor-kB and SP1) and cytokines (tumor necrosis fac-
tor-a, transforming growth factor-b1, and interleukin-
1b).23–26 Although proteolytic activity of PR3 is involved in
processing these molecules, there are accumulating
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data that indicate that PR3 can have direct effects on
intracellular processes in the absence of proteolytic ac-
tivity. For example, a secreted, inactive proform of PR3 is
shown to down-modulate DNA synthesis in normal hema-
topoietic progenitor cells. The inhibitory effect of secreted
PR3 is reversible by granulocyte-macrophage colony-
stimulating factor, implying that PR3 can function as a
counterbalance to regulators of proliferation.27 Enzymat-
ically inactive PR3 has been shown to induce interleu-
kin-8 production, whereas enzymatic activity is essential
for elastase to stimulate this effect.28 We have reported
that inactive PR3 induced apoptosis of bovine pulmonary
artery endothelial cells29 and subsequent studies con-
firmed these findings.30 Hence, PR3 seems to be a mul-
tifunctional protein endowed with the capacity to influ-
ence cell cycle, differentiation, and cell death.
It has been suggested that pulmonary injury and renal
glomerular damage may be caused by the MPO system.
MPO degrades H2O2 in the presence of chloride to pro-
duce hypochlorite (OCl2). The products of the MPO-
H2O2-chloride system are powerful oxidants that can
have profound biological effects. When MPO and H2O2
are released to the outside of the cell, a reaction with
chloride can induce damage to adjacent tissue and thus
contribute to the pathogenesis of disease.13,14
The important issue addressed by the study presented here
is the mechanism of neutrophil-mediated damage to endothe-
lial and epithelial cells during inflammation. We investigate
whether or not granule proteins, PR3 and MPO, are internal-
ized into endothelial and epithelial cells and whether internal-
ization has an effect on these cells. Precedence for nuclear
import of granule proteases is provided by reports showing
that granzyme B, a protease from granules of T lymphocytes
and natural killer cells and a homologue of PR3, can be trans-
ported to the nucleus in treated Cos cells and the cells die by
apoptosis.31 Signal transduction events, associated with gran-
zyme B-induced apoptosis, included activation of the cyclin-
dependent kinase cdc-2.32 Further, it was shown that specific
inhibitors of the proteolytic activity of granzyme B had no effect
on the nuclear import, implying that proteolytic activity was not
essential for nuclear targeting.
We report that human endothelial cells bind, seques-
ter, and route neutrophil proteins, PR3, and MPO, from
the cell surface to the nucleus where they co-localize with
chromatin. PR3 internalization is concomitant with apo-
ptosis in contrast to MPO. Epithelial cells do not have the
capacity to internalize PR3 and do not die by apoptosis.
The apoptotic function of PR3 was mapped to a 100-
amino acid fragment of the molecule, which contains no
component of the catalytic triad. MPO internalization is
not restricted by cell type, implying that the mechanism is
not the same as that for PR3 internalization. Internalized
MPO confers increased intracellular oxidant production.
Materials and Methods
Preparation of Granule Proteins
Granule proteins were isolated from leukocytes of human
donors with leukemia.29 PR3 was purified by a monoclo-
nal anti-PR3 affinity column (monoclonal anti-PR3 IgG,
12-1D6-1D4, developed in our laboratory) and a Bio-Rex
70 column (Bio-Rad Laboratories, Richmond, CA) and
MPO by a Resource S cation exchange column (Pharma-
cia, Uppsala, Sweden) and a Superdex 200 gel filtration
column (Pharmacia).29 The purity of PR3 and MPO was
determined by amino acid sequencing, enzyme-linked
immunosorbent assay, Western blot analysis, and enzy-
matic activity. Enzymatic activity of MPO was 172 U/mg
protein using 4-aminoanipyrine as substrate.33 PR3 pro-
teolytic activity was very low, using Boc-Ala-Onp as sub-
strate.29 Protein preparations were determined to be en-
dotoxin-free. Proteolytically active PR3 (109 U/mg
protein) was a generous gift from Dr. J. Wieslander
(Wieslab AB, Lund, Sweden). Triton X-100 was removed
from active PR3 using Extracti-Gel D AffinityPak deter-
gent-removing column (Pierce, Rockford, IL).
Cell Culture Conditions
Pooled human umbilical vein endothelial cells (HUVECs),
single-donor human umbilical arterial endothelial cells
(HUAECs), single-donor human lung microvascular en-
dothelial cells (HMVEC-Ls), and single-donor human
small airway epithelial cells (SAECs) were obtained from
Clonetics (San Diego, California, CA). HUVECs and
HUAECs were cultured in EGM BulletKit, HMVEC-Ls
in EGM-2 MV BulletKit, and SAECs in SAGM BulletKit
media (Clonetics). Media contained growth factors, 2%
fetal calf serum (FCS), antibiotics, and other supple-
ments, but there was no FCS in the SAGM BulletKit me-
dium. HUVECs and SAECs, passage 3 or 4, and HUAECs
and HMVEC-Ls, passage 5 or 6, were used for experi-
ments. Monkey epithelial cells (Cos-7) were maintained in
Dulbecco’s modified Eagle’s medium-H, 10% fetal bo-
vine serum, and antibiotics. EA.hy926 cells (HUVECs
fused to A549 human lung epithelial carcinoma) were
cultured in the same medium plus hyproxanthine aminop-
terin thymidine (HAT) supplement.
Translocation of Granule Proteins into Cells
Cells on microscope cover glasses were incubated with
10 mg/ml of PR3 or MPO for 5 minutes to 16 hours at 37°C
in media without growth factors or FCS. For immunofluo-
rescent staining, cells were fixed with 2% paraformalde-
hyde in phosphate-buffered saline (PBS), permeabilized
with acetone, and blocked with 0.2 mol/L glycine and 5%
donkey serum in PBS. Primary antibodies were rabbit
anti-PR3 (Wieslab AB) or rabbit anti-MPO antibody
(DAKO, Carpinteria, CA) and secondary antibody, fluo-
rescein isothiocyanate-conjugated affinipure F(ab9)2
fragment donkey anti-rabbit IgG (H1L) (Jackson, West
Grove, PA), was used. Cells were mounted and viewed
by a Nikon FXA research light microscope (Nikon, Gar-
den City, NY) for standard immunofluorescence staining.
A Zeiss confocal laser-scanning microscope LSM 110
(Carl Zeiss, Thornwood, NY) for confocal immunofluores-
cence staining, with an optical section thickness is 0.5
mm using the 633 plan apo 1.4 NA objective. The cells
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were analyzed from top to bottom in 15 different planes.
The appropriate negative controls were performed con-
currently, consisting of untreated cells stained with pri-
mary antibodies and/or secondary antibody, PR3-treated
cells with anti-MPO antibody as primary antibody and
MPO-treated cells with anti-PR3 antibody as primary an-
tibody, and treated cells with primary antibodies or sec-
ondary antibody alone.
For immunogold labeling, cells were processed ac-
cording to the methods described by Madden.34 Sam-
ples were blocked in 5% goat serum, incubated with
primary antibodies, monoclonal anti-PR3 IgG (4A3)
(Wieslab AB) or polyclonal anti-MPO IgG (DAKO), for 2
hours, and subsequently incubated with secondary anti-
bodies, goat anti-mouse 10-nm colloidal gold (Amersham
Life Science, Arlington Heights, IL) for monoclonal pri-
mary antibody or protein A 10 nm colloidal gold (Ted
Pella, Redding, CA) for polyclonal primary antibody, for 1
hour at room temperature. The grids were observed and
photographed using a LEO EM-910 transmission electron
microscopy (LEO Electron Microscopy, Thornwood, NY).
The appropriate negative controls were performed con-
currently, consisting of untreated cells stained with anti-
PR3 IgG or anti-MPO IgG and treated cells stained with
normal mouse or rabbit IgG (DAKO).
Assessment of Apoptosis
Cells in flasks were treated with 1 to 10 mg/ml of isolated
and enzymatically inactive PR3 or 1 to 100 mg/ml MPO for
6 to 24 hours in medium containing 2% FCS, but without
growth factors. For all assays, both detached and ad-
hered cells were harvested and combined. Apoptosis
was assessed by characteristic morphological changes
using an UV light microscope (Nikon), and by DNA con-
tent using flow cytometry. For UV light microscopy, cells
were stained with DNA dyes, either 1 mg/ml 49,6-dia-
midino-2-phenylindole (DAPI) (Sigma, St. Louis, MO) or
20 mg/ml propidium iodide (Sigma). Apoptotic cells were
identified by chromatin condensation and fragmenta-
tion.35 Data reported was from six samples of at least
three independent experiments, counting 500 cells from
randomly selected fields. For flow cytometry, cells were
fixed in 70% ethanol/PBS, incubated at 4°C overnight,
and resuspended in propidium iodide staining mixture,
as described previously.29 DNA content was determined
with a FACScan flow cytometer (Becton Dickinson Immu-
nocytometry Systems, San Jose, CA) linked to a Cicero/
Cyclops system (Cytomation, Fort Collins, CO) for data
acquisition and analysis. Apoptotic cells were identified
by a decrease in DNA content resulting in an apoptotic
subG0/G1 population peak. At least 20,000 cells were
analyzed in each sample and data were reported from at
least three independent experiments.
Subcloning of PR3-N, PR3-M, and PR3-C
cDNA Sequences
PR3cDNA/pAcC4 plasmid was a generous gift from Dr.
Joelle E. Gabay, Cornell University Medical College. Nu-
cleotides 1–313 (PR3-N), 314–604 (PR3-M), and 620–
741 (PR3-C) were amplified by polymerase chain reac-
tion (PCR). Primers were designed to generate restriction
sites at each end and a kozak sequence at the 59 end.
Parameters were 30 cycles of 94°C for 30 seconds, 62°C for
30 seconds, and 72°C for 2 minutes. The primers for PR3-N
cDNA were 59-GATATCGCCACCATGGGCGCTCACCG-
GCCCC-39 (forward) and 59-TGGAATTCTCTGAGCCAC-
CGAGAAGTG-39 (reverse); PR3-M cDNA were 59-GATAT-
CGCCACCATGGGCGTGTTTCTGAACAACTACGAC-39 (for-
ward) and 59-TGGAATTCTTCCGAAGCAGATGCCGGC-
CTT-39 (reverse), and PR3-C cDNA primers were
59-GATATCGCCACCATGGGCCTGATCTGTGATGGCAT-
CATC-39 (forward) and 59-TGGAATTCTCAGCGTGGA-
ACGGATCCAGT-39 (reverse). Amplification products
were subcloned into pCR-Blunt (Zero Blunt PCR Cloning
Kit; Invitrogen, Carlsbad, CA) and sequenced using an
M13 forward primer (59-GTAAAACGACGGCCAG-39)
(UNC-CH Automated DNA Sequencing Facility, Chapel
Hill, NC). Insert was retrieved from pCR-blunt and sub-
cloned into pcDNA3.1(2)/Myc-HisA (Invitrogen)
Analysis of Apoptosis Induced by PR3
Fragments
Cos-7 cells were electroporated 24 hours after trypsiniza-
tion with 30 mg of plasmid DNA in serum-free RPMI at 300
V and 960 mF using the Gene Pulser II Electroporation
System (Biorad, Hercules, CA). Cells were cultured for 48
hours and conditioned medium was collected, centri-
fuged, and added to EA.hy926 cells. Apoptosis was
quantitated by FACScan analysis of terminal dUTP nick-
end labeling (TUNEL) cells using fluorescein isothiocya-
nate-dUTP and terminal transferase (TdT) (Boehringer
Mannheim, Mannheim, Germany). Briefly, the cells were
fixed with 1% paraformaldehyde in PBS and permeabil-
ized with 70% ethanol and labeling reaction was per-
formed. One half of each cell sample was used to deter-
mine background fluorescence by omitting TdT from the
reaction mixture. The TdT was added to the second half
and increases in fluorescence (FL1) were evaluated.
Clumps and doublets were excluded by using forward
scatter versus propidium iodide fluorescence (FL2-W).
Detection of Intracellular Oxidants
Generated by MPO
Intracellular oxidants generation was detected by oxida-
tion of nonfluorescent dihydrorhodamine (DHR) (New
Concept Scientific. Burlington, Ontario, Canada) to fluo-
rescent rhodamine. Cells were incubated with 10 mmol/L
DHR for 1 hour in medium without FCS or growth factors,
with the subsequent addition of MPO (1 to 50 mg/ml) or
PR3 (1 to 10 mg/ml) at 37°C for 4 to 24 hours. Intracellular
oxidant generation was determined by three methods.
Cell fluorescence was observed by UV light microscopy.
By flow cytometry, cells were harvested with trypsin/eth-
ylenediaminetetraacetic acid and cell fluorescence were
examined in FL1 green channel in which at least 20,000
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cells were analyzed. For fluorometry, treated cells were
washed, harvested, and lysed by sonication in 20 mmol/L
Tris-HCl, pH 7.4, buffer. The fluorescence of cell lysates
was measured by a fluorometer FLUOstar 403 (BMG Lab
Technologies, Offenburg, Germany), 5 time flashes per
sample (excitation wavelength of 485 nm, emission wave-
length of 538 nm).36 For blocking studies, MPO was
pre-incubated with a 10-fold dose of catalase (Calbio-
chem, La Jolla, CA) for 30 minutes before the addition to
cells. The appropriate negative controls were performed
concurrently, consisting of cells incubated with medium
or DHR alone, and no cell plate incubated with DHR and
granule proteins.
Statistical Analysis
Analysis of variance was used to determine whether any
differences between group means were seen at specific
dose and time points within each experiment. When over-
all differences were found within the experiment, Dun-
nett’s t-test was used to further compare means of each
treatment and its associated dose to the mean of the
control group specific to the experiment.37 This test eval-
uates the minimum significant difference between each
group and control as compared to the critical value of
Dunnett’s T at the P value of 0.05, whereas controlling for
multiple testing. PROC ANOVA and PROC GLM in SAS
were used for calculating the statistical analyses (SAS/
STAS User’s Guide, SAS Institute, Cary, NC, 1989).
Results
Internalization
Translocation of PR3 into Endothelial Cells
To examine potential mechanisms of PR3-induced ap-
optosis, we determined whether endothelial cells had the
capacity to internalize PR3. PR3-treated cells were exam-
ined by three standard techniques: immunofluorescence
microscopy, immunofluorescence confocal laser scan-
ning microscopy, and electron microscopy. By immuno-
fluorescence microscopy, HUVECs treated with inactive
PR3 showed surface and intracellular staining by 10 min-
utes (Figure 1B). HUVECs that had not been exposed to
PR3 did not show staining (Figure 1A and Figure 2A).
After 2 hours, the intensity of the fluorescence increased,
indicating that the level of PR3 in the cytoplasm of the cell
had increased (Figure 1C). To confirm these data and to
address the issue of nuclear localization, the PR3-treated
cells were analyzed using confocal laser scanning mi-
croscopy. Selected micrographs are shown in Figure 2.
PR3 staining was detected on the cell surface, with dif-
fuse staining in both the cytoplasm and the nucleus by 10
minutes (Figure 2B). By 2 hours, the level of PR3 staining
increased, indicating that PR3 uptake continued through-
out the 2 hours of incubation (Figure 2C).
Electron microscopy was used to study the compart-
mentalization of inactive PR3, once inside the cell. Se-
lected micrographs are shown in Figure 3. After 10 min-
Figure 1. Assessment of internalization by immunofluorescence microscopy. Photomicrographs of HUVECs (A–C and E–G) and SAECs (D and H). Untreated
HUVECs did not show staining with either anti-PR3 antibody (A) or anti-MPO antibody (E). HUVECs incubated with PR3 (B) (10 mg/ml) or MPO (F) (10 mg/ml)
displayed weak intracellular staining by 10 minutes. HUVECs treated with PR3 (C) or MPO (G) for 2 hours exhibited prominent intracellular staining. SAECs treated
with PR3 for 2 hours (D) were negative for intracellular staining; SAECs treated with MPO (H) showed prominent staining.
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utes of treatment, PR3 was detected in cytoplasmic
extrusions (Figure 3A). We also observed PR3 on the
surface membrane, at attachment plaques, in the nu-
cleus and in the nucleoli (data not shown). By 2 hours,
PR3 was localized in the nucleus and associated with
nuclear heterochromatin (Figure 3C), in nucleoli, in the
cytoplasm, and in secondary lysosomes, but not on the
cell surface or in attachment plaques (data not shown).
Endothelial cells harvested from artery (HUAECs) and
lung microvascular (HMVEC-Ls), when incubated with
PR3, showed staining patterns similar to those described
above for HUVECs (data not shown).
Translocation of MPO into Endothelial Cells
We determined if endothelial cells internalize MPO.
Analysis of MPO-treated cells showed that MPO was
translocated into HUVECs with a staining pattern similar
to that of PR3. Examination of HUVECs treated with MPO
for 10 minutes showed weak intracellular staining, as
assessed by immunofluorescence microscopy (Figure
1F). After 2 hours, strong cytoplasmic staining was ob-
served displaying a punctate pattern (Figure 1G). Anal-
ysis by confocal laser scanning microscopy showed
prominent surface membrane staining of MPO by 10
minutes (Figure 2F), with some staining in the cytoplasm
and nucleus, and by 2 hours a strong cytoplasmic signal
was detected with some nuclear staining (Figure 2G).
By electron microscopy, MPO was localized with het-
erochromatin in the nucleus within 10 minutes (Figure
3B). Additional staining was observed at the plasma
membrane, in the cytoplasm, at attachment plaques, in
the nucleus and in the nucleoli (data not shown). Within 2
hours, MPO could be localized to secondary lysosomes
(Figure 3D), in the cytoplasm, nucleus and nucleoli, but
not on the cell surface and not in attachment plaques
(data not shown). Endothelial cells harvested from artery
(HUAECs) and lung microvascular (HMVEC-Ls), when
incubated with MPO, showed staining patterns similar to
those described above for HUVECs (data not shown).
Translocation of MPO, but Not PR3, into
Epithelial Cells
To determine whether translocation of PR3 and MPO
was a phenomenon specific to endothelial cells, or if
other cell types could internalize these proteins, epithelial
cells (SAECs) were treated and examined as described
above. Internalization of PR3 could not be detected at
any time point, with very weak surface staining at 2 hours
(Figure 1D), and similar results were obtained by confo-
cal microscopy and electron microscopy (Figure 2D).
Surprisingly, SAECs, treated with PR3, began to float off
of the plate at 2 hours (;30%) to 4 hours (;60%). We
analyzed the cells at multiple time points before detach-
ment (5 minutes, 10 minutes, 15 minutes, 30 minutes, 1
Figure 2. Assessment of internalization by immunofluorescence confocal laser-scanning microscopy. Photomicrographs of HUVECs (A–C and E–G) and SAECs
(D and H). HUVECs treated with medium alone did not show staining with either anti-PR3 antibody (A) or anti-MPO antibody (E). HUVECs treated with PR3 (10
mg/ml) (B) or MPO (10 mg/ml) (F) displayed surface staining and weak intracellular staining by 10 minutes. HUVECs treated with PR3 (C) or MPO (G) for 2 hours
resulted in intracellular staining with prominent staining in the cytoplasm. SAECs treated with PR3 for 2 hours were negative for intracellular staining (D). SAECs
treated with MPO for 2 hours showed strong cytoplasmic staining (H).
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hour, and 2 hours), and after detachment (4 hours) for
PR3 staining. Of cells that were still attached at 2 hours,
no PR3 internalization was detected. We reasoned that,
even if the SAECs had fewer receptors for PR3, some
positivity should have been detected by this time.
In contrast, MPO was internalized by SAECs and by 2
hours prominent staining was localized around the nu-
cleus (Figure 1H). Confocal microscopy showed similar
staining (Figure 2H). Analyses of internalization by elec-
tron microscopy showed staining patterns similar to those
described above for HUVECs, with the exception that
MPO was not found in the nucleus in SAECs (data not
shown). These data imply that MPO may enter SAECs
through a mechanism different from that of PR3.
These studies indicate that neutrophil granule proteins,
MPO and PR3, cross the endothelial cell membrane. The
electron microscopy studies indicate that both proteins
can localize to the nucleus. We report that this phenom-
enon is not unique to endothelial cells harvested from a
specific site, but is a common feature observed in
HUVECs, HUAECs, and HMVEC-Ls. Interestingly, lung
small airway epithelial cells do not seem to have the
capability to take up PR3, but are highly receptive to MPO
internalization, strongly suggesting that the mechanisms
of internalization are unique.
Association of Apoptosis with Internalization of PR3,
but Not MPO
To determine whether there is an association between
internalization of PR3 and PR3-induced apoptosis, endo-
thelial cells were treated with inactive PR3 and apoptosis
was quantified. Flow cytometry was used to detect cells
with a less than G0/G1 DNA content, indicative of apo-
ptosis, displayed as a subG0/G1 peak (Figure 4A). A
dose- and time-dependent increase in apoptosis was
found in PR3-treated HUVECs, compared to controls:
19.9 6 6.7% versus 7.6 6 1.7% with 10 mg/ml for 12
hours; 16.0 6 3.7% versus 8.0 6 3.0% with 5 mg/ml for 24
hours; and 28.4 6 1.1% versus 8.0 6 3.0% with 10 mg/ml
for 24 hours.
Apoptotic cells exhibiting nuclear fragmentation were
quantified using UV light microscopy. Untreated HUVECs
revealed uniform nuclei and intact plasma membranes
(Figure 4B). HUVECs treated with PR3 demonstrated
fragmented nuclei of different sizes (Figure 4C). A statis-
tically significant increase in apoptotic HUVECs was ob-
served in a dose- and time-dependent manner with
11.7 6 2.8% apoptotic cells in 10 mg/ml of PR3 for 24h
(Figure 4, D and E). To determine whether inactive PR3
would induce apoptosis in endothelial cells harvested
Figure 3. Assessment of internalization by electron microscopy. Electron micrographs of HUVECs stained by immunogold labeling. PR3 (A) (gold particles,
arrows) was present in cytoplasmic extensions by 10 minutes and in the nucleus associated with heterochromatin by 2 hours (C); MPO (B) (gold particles,
arrows) was associated with nuclear heterochromatin by 10 minutes and by 2 hours was detected in the cytoplasm and in secondary lysosomes (D).
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from sites other than umbilical vein, cells from umbilical
artery and lung microvasculature were analyzed for
fragmented, condensed DNA. Arterial endothelial cells,
HUAECs, treated with 10 mg/ml of PR3 for 24 hours
showed 10.3 6 3.1% apoptosis, whereas lung microvas-
cular cells, HMVEC-Ls, showed only 3.0 6 1.8%. Com-
pared with control values of 1.5 6 1.1% in HUVECs, 1.3 6
0.8% in HUAECs and 1.0 6 0.9% in HMVEC-Ls, the
changes were statistically significant with PR3 treatment
in HUVECs and HUAECs, but not in HMVEC-Ls.
These results provide evidence that PR3-induced ap-
optosis may be linked with internalization of the protein. If
this hypothesis is correct, then SAECs, which did not
internalize PR3, should not undergo apoptosis with PR3
treatment. Examination of PR3-treated SAECs showed no
morphological changes, by UV light microscopy, indica-
tive of apoptosis, nor were any apoptotic cells detected
by flow cytometry (0.69% with 10 mg/ml of PR3 for 7
hours; controls 0.68%). Of note, SAECs treated with in-
active PR3 began to detach from the dish by 2 hours and
a majority of the cells were floating by 7 hours (;90%).
Both attached and detached cells were harvested ana-
lyzed and no apoptosis was detected.
We determined whether internalization of MPO by
HUVECs had an apoptosis-inducing effect. Assessment
of nuclear fragmentation by UV light microscopy showed
that MPO did not trigger apoptosis, even at doses up to
100 mg/ml and for a time up to 24 hours (Figure 4, D and
E). Nor were any apoptotic cells (above background)
detected by flow cytometry, including cells treated with
MPO concentrations ranging from 1 to 100 mg/ml for 6 to
24 hours. Additionally, no apoptosis was detected in
HUAECs, HMVEC-Ls and SAECs after MPO internaliza-
tion (data not shown).
These studies strongly suggest that PR3-induced ap-
optosis requires internalization. The mere process of in-
ternalization of extracellular proteins alone is not suffi-
cient to cause apoptosis, based on data showing that
MPO internalization does not result in apoptosis.
Identification of a Noncatalytic Domain of PR3 with
Apoptotic Function
We have proposed that the apoptosis-inducing effects
of PR3 described above were independent of proteolytic
activity. The potential exists that the PR3 preparations
used in those studies had very low levels of proteolytic
activity. We hypothesized that if the proteolytic activity of
PR3 is solely responsible for the apoptotic effects on
HUVECs, then blocking this activity should block apopto-
sis. To test this, proteolytically active PR3 was used to
induce apoptosis in HUVECs, plus and minus inhibitors.
We found that addition of 2% fetal calf serum blocked
only 35.7% apoptosis and addition of a-1-antitrypsin (a1-
AT) blocked only 36.1%. Because not all apoptosis was
blocked, the data support the hypothesis that PR3 can
induce apoptosis through a mechanism (s) that is inde-
pendent of its proteolytic function. However, there is the
possibility the protease inactivators were only partially
effective in blocking PR3 activity. Perhaps they are effec-
tive in vitro but once the proteinases enter the cell, inhib-
itor activity is lost. To address this issue, we developed a
system to produce PR3 fragments that did not contain the
full component of sequences required for the catalytic
site. Based on crystal structure studies (Figure 5A), only
one of three components of the catalytic triad was in the
first one-third of the molecule, the second component
was in the middle portion and the third component was in
the last third of the molecule. The catalytic triad forms the
active site through protein folding.38 Therefore, three
unique fragments of PR3 were generated, each of which
Figure 4. PR3 internalization induces apoptosis. A: Flow cytometric analysis.
HUVECs treated with PR3 showed a concentration-dependent increase in
apoptotic cells (shown as a subG0/G1 peak). UV light microscopy of DAPI-
stained cells showed uniform nuclei in the untreated group (B); PR3 treated
cells (12 hours) showed an apoptotic morphology with nuclear fragmenta-
tion (C). Dose-response curve showing percentage of apoptotic HUVECs (24
hours), as assessed by UV light microscopy (D). Time-dependent response
curve of cells that were treated with 10 mg/ml PR3 or 100 mg/ml MPO (E). *,
Statistically different from control (P 5 0.0001). Values are means 6SEM; n 5
6. PR3, but not MPO, induces HUVEC apoptosis in a dose- and time-
dependent manner.
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contained only one portion of the catalytic triad. These
were subcloned into a mammalian expression vector that
contains a myc-epitope tag and a histidine tail
(pcDNA3.1 myc-his). Cos-7 cells were transiently trans-
fected with vectors coding for the N-terminal peptide
(amino acids 2–104), middle peptide (amino acids 105–
204), or the C-terminal peptide (amino acids 205–247)
and stained with a DNA dye to detect DNA fragmentation.
Cos-7 cells transfected with the C-terminal peptide died
by apoptosis 24 hours after transfection, showing frag-
mented nuclei (Figure 5B). Cells transfected with PR3-N
or PR3-M did not show this morphology (data not shown).
Having identified a fragment of PR3 with death-induc-
ing function in Cos-7 cells, the critical question arises of
whether this fragment will have a similar effect on endo-
thelial cells. In this experiment the endothelial-like cell
line, EA.hy.926, was used to test the effects of condi-
tioned medium from culture plates of Cos-7 cells that had
been transfected with PR3-N, PR3-M, or PR3-C 48 hours
previously. The high level of expression of the transfected
plasmid in Cos-7 cells generally results in the release of
peptide into the medium. EA.hy.926 cells were used in
this study because HUVECs require special medium;
therefore, it was difficult to interchange the media with
Cos-7 cells. However, we could interchange the media
used for growing EA.hy.926 cells and Cos cells. Apopto-
sis was monitored by FACScan analysis of TUNEL-la-
beled cells, as shown in Figure 5. The terminal trans-
ferase enzyme (TdT) required for end-labeling of the
fragmented DNA was omitted to set parameters of back-
ground fluorescence (Figure 5C). Increases because of
addition of TdT indicate TUNEL-labeled apoptotic cells.
EA.hy926 incubated with conditioned medium (24 hours)
from PR3-C-transfected cells had 20 6 3.0% TUNEL-
positive cells (Figure 5D). PR3-M-transfected cells had
4.75 6 0.75% positive cells and PR3-N-transfected cells
had 1.07 6 2.6%. The data indicate that the C-terminal
domain of PR3 can function as a pro-apoptotic molecule,
at least in the cell types tested, whereas the N-terminal,
and middle fragments cannot. These findings support the
hypothesis that the mechanism of PR3-induced apopto-
sis does not necessarily require its proteolytic function.
Association of Increased Intracellular Oxidation with
Internalization of MPO, but Not PR3
The data presented above indicate that internalization
of PR3 can induce apoptosis in endothelial cells, but
internalization of MPO does not, thus raising the question
of whether MPO, once inside an endothelial cell, has any
measurable function that could affect cellular integrity. To
test this, intracellular oxidant generation was determined
by monitoring the oxidation of nonfluorescent DHR to
fluorescent rhodamine. By UV light microscopy, HUVECs
incubated with MPO in the presence of DHR showed the
generation of oxidants, displayed as green cytoplasmic
fluorescence (Figure 6B), whereas cells incubated with
DHR alone did not (Figure 6A). As analyzed by flow
Figure 5. Identification of a noncatalytic domain of PR3 with apoptotic function. Ribbon model of PR3 molecule (A): N-terminal fragment (PR3-N, light gray),
middle fragment (PR3-M, white), and C-terminal fragment (dark gray, PR3-C). Cos-7 cells (B) transfected with PR3-C vector, stained with DAPI, show nuclear
fragmentation. Flow cytometric analysis (C and D) of TUNEL-labeled EA. Hy926 cells treated with conditioned medium containing PR3-C. Limits were set using
the minus TdT (C) to control for background fluorescence. Plus TdT (D) shows increased fluorescence indicative of apoptotic cells.
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cytometry, MPO incubation in the presence of DHR for 6
to 24 hours induced an increase of fluorescence intensity
in a dose- and time-dependent manner (Figure 6, E–G).
MPO increased oxidant levels by 60% with 1 mg/ml, by
99% with 5 mg/ml, and by 136% with 25 mg/ml treatment
for 6 hours and by 349% with 25 mg/ml treatment for 24
hours (Figure 6, F and G). Using fluorometric methods,
lysates of HUVECs treated with 25 mg/mg MPO and DHR
for 6 hours showed a 1.83-fold increase in oxidant pro-
duction. Similar to HUVECs, SAECs incubated with MPO
in the presence of DHR showed the generation of oxi-
dants, displayed as green cytoplasmic fluorescence by
UV light microscopy (Figure 6D), whereas cells incu-
bated with DHR alone did not (Figure 6C). As measured
by flow cytometry, oxidant levels increased by 208% with
25 mg/ml MPO treatment for 6 hours. Using fluorometric
methods, lysates of SAECs treated with 25 mg/ml MPO for
6 hours showed a 1.78-fold increase. If MPO treatment
results in increased levels of reactive oxygen species
leading to increased levels of H2O2, then addition of
catalase would result in reduced oxidant levels. Catalase
directly catalyzes decomposition of H2O2 to ground-state
O2.
39 Although catalase is not cell permeable, H2O2 can
freely diffuse across cell membranes and therefore would
be available for interaction with catalase in the tissue
culture medium.40 Addition of catalase significantly
blocked MPO-induced increases in reactive oxygen spe-
cies (Figure 6, F and G), in contrast to 1 to 10 mg/ml of
PR3 for 6 to 24 hours, which did not induce generation of
intracellular oxidants in either HUVECs or SAECs (data
not shown). The data indicate that MPO is functionally
active once internalized into HUVECs or SAECs.
Discussion
Our results provide new insights into potential mecha-
nisms of neutrophil-associated tissue damage in inflam-
mation. We report that endothelial cells bind, sequester,
and route neutrophil PR3 and MPO from the cell surface
Figure 6. Internalization of MPO results in generation of intracellular oxidants. Untreated HUVECs (A) and SAECs (C) incubated with DHR alone for 6 hours
showed no cytoplasmic fluorescence. HUVECs (B) and SAECs (D) incubated with MPO (25 mg/ml) plus DHR for 6 hours showed increased intracellular oxidant
generation. Flow cytometric analysis (E) showed an increase in mean of fluorescence intensity in HUVECs treated with 5 or 25 mg/ml MPO. Flow cytometric
analysis (F and G) showing a dose- and time-dependent increase in intracellular oxidants generated by MPO treatment. Addition of catalase resulted in decreased
intracellular oxidant generation. *, Statistically different from DHR alone (P , 0.05). Values are means 6SEM; n 5 3. MPO causes the increase of intracellular
oxidant generation in HUVECs in a dose- and time-dependent manner and the increase can be blocked by catalase.
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through the cell. To our knowledge, after an exhaustive
search of the database, this is the first report that neutro-
phil granule proteins, PR3 and MPO, are capable of
entering cells and causing toxic events. Because PR3
and MPO are both released into the endothelial cell mi-
croenvironment during inflammation, our data suggest
that PR3 and MPO induce changes in endothelial cells
through a mechanism requiring internalization of the pep-
tides. The significance of our data over what was previ-
ously known is that it adds a new dimension to mecha-
nisms of PR3 and MPO effects, and future research will
need to address potential interactions with cytoplasmic
and/or nuclear proteins. Therefore, in addition to the con-
ventional role of neutrophil proteins in mediating extra-
cellular matrix degradation, we propose that granule pro-
teins play a far more complex role in affecting endothelial
cells than previously described.
Internalization of inactive PR3 seems to be linked with
activation of apoptosis. The mechanism of PR3 internal-
ization may be unique, compared to that of MPO; how-
ever, a systematic study will be required to confirm these
initial observations.
We have demonstrated that the C-terminal domain of
the PR3 molecule carries an apoptosis-inducing function,
independent of its proteolytic function. The data imply
that inactive PR3 may exert its action through penetration
into the endothelial cell cytoplasm and/or nucleus and
perhaps even the nucleolus. It now becomes obvious that
understanding the mechanism of PR3-induced effects
will be dependent on elucidation of natural PR3-interact-
ing proteins. Some known substrates of PR3 are HSP28,
nuclear factor-kB, and Sp1, proteins found in both the
cytoplasm and the nucleus.21–23 If inactive PR3 were to
complex with these proteins, it is feasible that their normal
functions could be altered, even in the absence of pro-
teolytic cleavage. In support of this proposal some par-
allels can be drawn with the extensively studied protease,
granzyme B, a cytotoxic T-cell granule protein with high
homology to the neutrophil PR3. Characterization and
identification of substrates demonstrated that granzyme
B recognizes an 80-kd nuclear protein and cytoplasmic
proteins of 50, 94, and 69 kd.41 The 69-kd protein bound
both the active and zymogen forms of granzyme B. The
C-terminal fragment of PR3 has an interesting structure
that may facilitate protein interactions and contribute to
its pathogenic effects. The only a-helical domain in the
PR3 molecule is one at the C-terminal end of the mole-
cule. The helix is downstream of a hinge region, facilitat-
ing rotation and movement of the helix in an arm-like
manner, which would allow this domain to interact with
other proteins.
There is accumulating evidence that some neutrophil
granule proteins have dual functions. Cathepsin G has a
death function associated with the C-terminal portion of
the protein, which has no proteolytic activity.42 Interest-
ingly, the amino acid sequence of this region of cathepsin
G is highly homologous to PR3-C, the region of PR3
containing the apoptosis-inducing function. Elastase has
a death function separable from and independent of its
proteolytic activity.43 It has recently been shown that
azurocidin is internalized into endothelial cells and is
targeted to mitochondrial compartments of the cell, but
not in the nuclear compartment.44 Interestingly, internal-
ized azurocidin markedly reduces growth factor depriva-
tion-induced apoptosis, and the authors have suggested
that uptake of exogenous azurocidin contributes to the
sustained viability of endothelial cells in the context of
locally activated neutrophils. The question arises of
whether azurocidin would block PR3-induced apoptosis,
thus revealing complexities of the balance/counterbal-
ance mechanisms of the neutrophilic system never be-
fore realized.
Endothelial cells have been shown to internalize two
other neutrophil granule proteins, lactoferrin45 and azuro-
cidin.46 Lactoferrin is thought to enter the endothelial cell
once complexed to binding sites on the cell surface for
cationic proteins, whereas azurocidin binds to endothe-
lial cell surface proteoglycans. However, neither of these
two proteins are proteases. Proteases that are internal-
ized by endothelial cells include renin and tissue plas-
minogen activator, both of which are internalized through
binding to the mannose receptor.47,48 The mechanism of
PR3 internalization has not been determined, however
Taekema-Roelvink and co-workers49 have shown that
PR3 interacts with a 111-kd membrane molecule of
HUVECs. Further identification of PR3 binding molecules
is currently under investigation.
MPO internalization has important implications in pin-
pointing mechanisms involved in oxidative damage in
vivo. MPO uses H2O2 to produce diffusible cytotoxic ox-
idants.14 Internalization of MPO resulted in increased
oxidant production through a catalase-inhibitable reac-
tion. This means that MPO substrate H2O2 was present in
these cells, in the absence of any other cytokine treat-
ment. Vascular endothelial cells have been shown to
produce basal levels of H2O2 at an intracellular site in the
vicinity of peroxisomes and at a second site near the cell
surface that is inaccessible to intracellular catalase.50 It
has been shown also that cultured cells have as much as
threefold greater rate of release of H2O2, in certain cul-
ture mediums.46 Therefore, it is highly possible that en-
dothelial cells of vessels have low levels of intracellular
H2O2. Titration of cellular H2O2 by MPO can result in
decreased production of hydroxyl radical, thereby mini-
mizing cell injury.51 H2O2 can react with superoxide anion
to form the highly reactive hydroxyl radical. Purified MPO
has been shown to strongly inhibit hydroxyl radical pro-
duction in a concentration-dependent manner.52 Al-
though MPO may have a protective effect in certain
cases, MPO can react with H2O2 to form hypochlorous
acid (HOCl), which is a more potent oxidant than H2O2,
and excess hypochlorous acid formation can result in
tissue damage. Active MPO has been shown to be a
component of human atherosclerotic lesions,53 and inter-
nalization of MPO could potentate this disease process.
In summary, our data indicate the release of granule
proteins by activated neutrophils and monocytes during
acute inflammation may result in direct toxic effects by
previously unrecognized mechanisms. The evidence in-
dicates that PR3 enters endothelial cells and induces
apoptosis through a function localized to the C-terminal
death domain. We are very interested in understanding
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how C-PR3 is activating apoptosis. Exploration of the
pathway(s) used by this fragment will require purified
peptide. Efforts to generate this reagent have thus far
been unsuccessful, because the C-PR3 fragment kills
many of the expression systems that we have tried to use.
In those systems that were not killed, we have yet to get
purified protein. Studying the effects of internalization of
neutrophil granule proteins or their fragments may well
prove to be very important in understanding mecha-
nism(s) of injury during acute inflammation.
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